Posted: August 13, 2012
Stalco Construction completes Genometrica Research Inc.'s U.S. Headquarters
Stalco Construction completed the U.S. Headquarters office and research facility for the molecular biology and DNA sequencing equipment designer and manufacturer, Genometrica Research Inc., a subsidiary of Lichtenstein-based Genometrica Ltd.
Stalco served as design/builder for the 4,500 s/f interior renovation project that encompassed a 600 s/f laboratory, ten private offices, an open plan administrative area, boardroom, meeting room, entrance and reception area, kitchenette, storage rooms and bathrooms.
"The $350,000 renovation has converted an outdated office space into a state-of-the-art research, product development and engineering laboratory," said Stalco project manager Joseph Solloch. "The lab section features an enclosed fume hood workstation by Lab Design, four Monoxivent Mini Arms exhaust vents with clear glass dome hoods, epoxy resin and wood countertops, VCT flooring, composite board cabinets, and steel lockers for parts and materials storage."
The office areas feature acoustical tile ceilings; broadloom carpeting; recessed luminescent lighting fixtures; gypsum board walls; Corian countertops in the bathrooms; and a glazed, storefront-type entrance.
Headquartered in Islandia, NY, with a regional office in New York City, Stalco Construction, Inc. is a full-service general contracting and construction management firm active in the Greater New York area and on Long Island. Building Design & Construction magazine ranks Stalco as the 75th largest general contractor in the United States. ENR New York magazine ranks Stalco as the 22nd largest contractor in the NY/NJ/CT Tri-state area.
Established in 1992, the firm builds commercial and institutional facilities for office, retail, educational, healthcare, governmental, entertainment, sports and worship clients. Stalco's personnel include professional engineers, architects, project managers, superintendents, and support staff. The value of the firm's on-going ground-up, interior, and capital improvement projects totals approximately $100 million.
Stalco's affiliate, Stalco International Group, designs and erects custom engineered buildings for developers and architects of commercial, office, institutional, public, and industrial structures. Stalco works in a partnership with Varco Pruden Buildings, a division of BlueScope Buildings North America, a world leader of the pre-engineered buildings industry.
Since the firm's inception, its leadership and employees have been involved in supporting the local community through responsible corporate citizenship and charity work. The company's principals, Kevin G. Harney and Alan Nahmias, co-founded Contractors For Kids (CFK), a not-for-profit organization supported by nearly 300 Long Island-based construction and real estate organizations. CFK provides assistance to children and their families impacted by health-related crisis.
Stalco's current and recent work includes the $8.4-million Battery Park City Community Center and the $15-million restoration of the landmark Pier A in Manhattan; the $24-million renovation of the Vaughn College of Aeronautics and Technology in Queens, NY; the new, $5.2-million Emergency Department at the Lincoln Medical and Mental Health Center in the Bronx; the $16.5-million renovation and expansion of the Long Beach High School in Lido Beach, NY; the $1.4-million Home Fair store at the Atlas Park Mall in Queens NY; the Ultra Diamonds jewelry store in Riverhead, NY; the $11.3-million renovation of the landmarked Erasmus Hall High School in Brooklyn, NY; the on-call Construction Management contract for the 780,000-square foot CA, Inc. Global Headquarters in Islandia, NY; and the $30-million expansion and renovation program for the Three Village Central School District in Suffolk County.
MORE FROM Long Island
Hauppauge, NY The Suffolk County Industrial Development Agency (IDA) has granted preliminary approval of a financial incentive package that will assist a manufacturer in expanding its business by manufacturing more prescription (Rx) pharmaceuticals in addition to its existing over-the-counter